Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report

Jiao,Xiao‑Dong; Luo,Xiu; Qin,Wen‑Xing; Yuan,Ling‑Yan; Zang,Yuan‑Sheng

doi:10.3892/mco.2016.782

Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report

Authors:
- Xiao‑Dong Jiao
- Xiu Luo
- Wen‑Xing Qin
- Ling‑Yan Yuan
- Yuan‑Sheng Zang
View Affiliations

Affiliations: Department of Medical Oncology, Changzheng Hospital, Shanghai 200070, P.R. China, Department of Hematology, Tongji Hospital of Tongji University, Shanghai 200065, P.R. China
Published online on: February 16, 2016 https://doi.org/10.3892/mco.2016.782
Pages: 824-826

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nab‑paclitaxel is a recently emerged chemotherapy drug, which is widely used for the treatment of multiple types of cancer. The prospects of this novel drug are very bright as a result of its higher efficacy and lower toxicity compared with paclitaxel. Hence, the side effect, even if rare, require attention in clinical practice. The present study described an unusual case of nab‑paclitaxel‑associated paralytic ileus. To the best of our knowledge, this is the first report to demonstrate that nab‑paclitaxel may lead to acute intestinal obstruction. Since nab‑paclitaxel will be used more frequently, this unusual side effect might be encountered by a clinical oncologist and must be treated correctly. This is the first reported case, to the best of our knowledge, of paralytic ileus caused by nab‑paclitaxel, which will be widely used as a novel anticancer drug.

View Figures

View References

1	Cecco S, Aliberti M, Baldo P, Giacomin E and Leone R: Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Saf. 13:511–520. 2014. View Article : Google Scholar : PubMed/NCBI
2	Yardley DA: Nab-Paclitaxel mechanisms of action and delivery. J Control Release. 170:365–372. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yardley DA, Hart L, Bosserman L, Salleh MN, Waterhouse DM, Hagan MK, Richards P, DeSilvio ML, Mahoney JM and Nagarwala Y: Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat. 137:457–464. 2013. View Article : Google Scholar : PubMed/NCBI
4	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
5	Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P and Zhang H: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
6	Koizumi W, Morita S and Sakata Y: A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol. 45:303–306. 2015. View Article : Google Scholar : PubMed/NCBI
7	Guarneri V, Dieci MV and Conte P: Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 13:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
8	Vishnu P and Roy V: Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer (Auckl). 5:53–65. 2011.PubMed/NCBI
9	Matsuoka N, Hasebe H, Mayama T and Fukuchi T: Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound-paclitaxel (Abraxane). Case Rep Ophthalmol Med. 2015:1812692015.PubMed/NCBI
10	Rivera E and Cianfrocca M: Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 75:659–670. 2015. View Article : Google Scholar : PubMed/NCBI
11	John P, Butler H and Saif MW: Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. Anticancer Res. 34:7267–7270. 2014.PubMed/NCBI
12	Rahman HT, Yeh S and Bergstrom CS: Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): Clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther. 29:360–362. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gardini Casadei A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, Burgio MA, Amadori D and Frassineti GL: Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 13:5422013. View Article : Google Scholar : PubMed/NCBI
14	Aapro MS, Martin C and Hatty S: Gemcitabine-a safety review. Anticancer Drugs. 9:191–201. 1998. View Article : Google Scholar : PubMed/NCBI
15	Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ and Ramondetta LM: Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 127:451–455. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yagihashi S, Tokui A, Kashiwamura H, Takagi S and Imamura K: In vivo effect of methylcobalamin on the peripheral nerve structure in streptozotocin diabetic rats. Horm Metab Res. 14:10–13. 1982. View Article : Google Scholar : PubMed/NCBI
17	Ide H, Fujiya S, Asanuma Y, Tsuji M, Sakai H and Agishi Y: Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clin Ther. 9:183–192. 1987.PubMed/NCBI